ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!ATAI Company Profile and Key Details
Atai Life Sciences N.V.
ATAI Stock Price Chart
Stock Price Today
Atai Life Sciences N.V. (ATAI) stock declined over -12.79%, trading at $1.50 on NASDAQ, down from the previous close of $1.72. The stock opened at $1.73, fluctuating between $1.50 and $1.73 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Company Information
| Employees | 83 |
| Beta | 1.23 |
| Sales or Revenue | $314.00K |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Atai Life Sciences N.V. (NASDAQ: ATAI) stock price is $1.50 in the last trading session. During the trading session, ATAI stock reached the peak price of $1.73 while $1.50 was the lowest point it dropped to. The percentage change in ATAI stock occurred in the recent session was -12.79% while the dollar amount for the price change in ATAI stock was -$0.22.
The NASDAQ listed ATAI is part of Biotechnology industry that operates in the broader Healthcare sector. Atai Life Sciences N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Jennifer Freiling
Director of Communications
Mr. Ryan Barrett
Gen. Counsel & Corporation Sec.
Dr. Rolando Gutierrez-Esteinou M.D.
Chief Medical Officer
Dr. Sahil V. Kirpekar M.D.
Chief Bus. Officer
Mr. Frank Stegert
Vice President of Investment & Venture Management
Ms. Anne Johnson
Chief Accounting Officer
Mr. Aaqil Anwar
Mang. of Corporation Fin. & Investor Relations
Ms. Madison Crawford
Senior Mang. of Accounting
Mr. Christian Angermayer
Founder & Chairman of the Supervisory Board
Mr. Florian Brand
Co-founder & Chief Executive Officer
Dr. Srinivas G. Rao M.D., Ph.D.
Co-Founder & Chief Scientific Officer
Mr. Stephen B. Bardin
MD & Chief Financial Officer
ATAI's closing price is 45.63% higher than its 52-week low of $1.03 where as its distance from 52-week high of $2.85 is -47.37%.
Number of ATAI employees currently stands at 83.
Official Website of ATAI is: https://www.atai.life
ATAI could be contacted at phone 498 921 539035 and can also be accessed through its website. ATAI operates from Krausenstrasse 9-10, Berlin, 10117, Germany.
ATAI stock volume for the day was 2.76M shares. The average number of ATAI shares traded daily for last 3 months was 2.76M.
The market value of ATAI currently stands at $290.99M with its latest stock price at $1.50 and 193.99M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com